# FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

> **NCT01896869** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 83 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Ipilimumab
- **BIOLOGICAL:** Vaccine
- **DRUG:** FOLFIRINOX

## Key facts

- **NCT ID:** NCT01896869
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2019-05-03
- **Final completion:** 2019-05-03
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2020-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01896869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01896869, "FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01896869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*